Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study-Reference-Cited by-同舟云学术

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

Published:2017-01-11 Issue:4 Volume:31 Page:997-1000
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ludwig H,Weisel K,Petrucci M T,Leleu X,Cafro A M,Garderet L,Leitgeb C,Foa R,Greil R,Yakoub-Agha I,Zboralski D,Vauléon S,Dümmler T,Beyer D,Kruschinski A,Riecke K,Baumann M,Engelhardt M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu20175.pdf

Reference15 articles.

1. Bouyssou JM, Ghobrial IM, Roccaro AM . Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett 2015; 380: 315–318.

2. Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 2014; 9: 118–128.

3. Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res 2006; 12: 6973–6977.

4. Vater A, Sahlmann J, Kroger N, Zollner S, Lioznov M, Maasch C et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther 2013; 94: 150–157.

5. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking barriers: Innovative approaches for skin delivery of RNA therapeutics;International Journal of Pharmaceutics;2024-08

2. Therapeutic Applications of Aptamers;International Journal of Molecular Sciences;2024-06-19

3. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM);Cell Communication and Signaling;2024-03-12

4. APTAMERS: NANOMATERIALS AS A POTENTIAL AGENT FOR ANTIVIRAL THERAPEUTIC DRUG DELIVERY DEVELOPMENT: A SYSTEMATIC LITERATURE REVIEW;International Journal of Applied Pharmaceutics;2024-01-07

5. Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome;Journal of Drug Delivery Science and Technology;2024-01